Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBT Margin (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of EBT Margin data on record, last reported at 8470.5% in Q3 2025.

  • For Q3 2025, EBT Margin fell 374193.0% year-over-year to 8470.5%; the TTM value through Sep 2025 reached 7838.42%, down 347301.0%, while the annual FY2024 figure was 5374.46%, 223010.0% down from the prior year.
  • EBT Margin reached 8470.5% in Q3 2025 per NWBO's latest filing, up from 12675.57% in the prior quarter.
  • Across five years, EBT Margin topped out at 1589.89% in Q1 2023 and bottomed at 12675.57% in Q2 2025.
  • Average EBT Margin over 5 years is 5770.92%, with a median of 4728.57% recorded in 2024.
  • Peak YoY movement for EBT Margin: skyrocketed 527288bps in 2022, then crashed -892165bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 3176.44% in 2021, then decreased by -2bps to 3249.41% in 2022, then decreased by -13bps to 3681.8% in 2023, then tumbled by -147bps to 9085.28% in 2024, then rose by 7bps to 8470.5% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 8470.5% in Q3 2025, 12675.57% in Q2 2025, and 5043.47% in Q1 2025.